IL6 and chronic kidney disease: Ziltivekimab, a novel monoclonal antibody targeting IL-6 has shown strong anti-inflammatory effects in patients with chronic kidney disease and high cardiovascular risk by significantly lowering hsCRP and other inflammatory markers [200].